Research programme: glioma diagnostics and therapeutics - Arch Biopartners

Drug Profile

Research programme: glioma diagnostics and therapeutics - Arch Biopartners

Alternative Names: MetaMx

Latest Information Update: 08 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arch Biopartners
  • Developer Arch Biopartners; d3 Medicine
  • Class Peptides
  • Mechanism of Action Diagnostic imaging enhancers; Magnetic resonance imaging enhancers; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioma

Most Recent Events

  • 08 Sep 2016 Preclinical development for Glioma (Treatment and Diagnosis) is underway in Canada (Arch Biopartners website, September 2016)
  • 07 Sep 2016 d3 Medicine has been acquired by Certara
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glioma in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top